Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
GT Biopharma, Inc. (GTBP) had Normalized Pre-Tax Income of $-13.16M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-13.16M |
|
-- |
|
-- |
|
$14.36M |
|
$-14.36M |
|
$1.20M |
|
$-13.16M |
|
|
Normalized Pre-Tax Income |
$-13.16M |
$-13.16M |
|
$-13.16M |
|
$-13.16M |
|
$-13.16M |
|
$-14.36M |
|
$-14.36M |
|
1.90M |
|
1.90M |
|
$-6.94 |
|
$-6.94 |
|
| Balance Sheet Financials | |
$4.23M |
|
-- |
|
-- |
|
$4.23M |
|
$5.90M |
|
-- |
|
-- |
|
$5.90M |
|
$-1.67M |
|
$-1.67M |
|
$-1.67M |
|
2.23M |
|
| Cash Flow Statement Financials | |
$-12.90M |
|
$12.89M |
|
$2.98M |
|
$1.08M |
|
$4.04M |
|
$2.96M |
|
$0.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.90M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
787.69% |
|
788.14% |
|
-311.01% |
|
788.14% |
|
$-0.75 |
|
$-6.80 |
|
$-6.80 |
|